Abstract
Owing to the rise in drug resistance in tuberculosis combined with the global spread of its causative pathogen, Mycobacterium tuberculosis (Mtb), innovative anti mycobacterial agents are urgently needed. Recently, we developed a novel primase–pyrophosphatase assay and used it to discover inhibitors of an essential Mtb enzyme, primase DnaG (Mtb DnaG), a promising and unexplored potential target for novel antituberculosis chemotherapeutics. Doxorubicin, an anthracycline antibiotic used as an anticancer drug, was found to be a potent inhibitor of Mtb DnaG. In this study, we investigated both inhibition of Mtb DnaG and the inhibitory activity against in vitro growth of Mtb and M. smegmatis (Msm) by other anthracyclines, daunorubicin and idarubicin, as well as by less cytotoxic DNA intercalators: aloe-emodin, rhein and a mitoxantrone derivative. Generally, low-μM inhibition of Mtb DnaG by the anthracyclines was correlated with their low-μM minimum inhibitory concentrations. Aloe-emodin displayed threefold weaker potency than doxorubicin against Mtb DnaG and similar inhibition of Msm (but not Mtb) in the mid-μM range, whereas rhein (a close analog of aloe-emodin) and a di-glucosylated mitoxantrone derivative did not show significant inhibition of Mtb DnaG or antimycobacterial activity. Taken together, these observations strongly suggest that several clinically used anthracyclines and aloe-emodin target mycobacterial primase, setting the stage for a more extensive exploration of this enzyme as an antibacterial target.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Green, K. D . & Garneau-Tsodikova, S . Resistance in tuberculosis: what do we know and where can we go? Frontiers Microbiol. 4, 208 (2013).
Wong, E. B ., Cohen, K. A . & Bishai, W. R . Rising to the challenge: new therapies for tuberculosis. Trends Microbiol. 21, 493–501 (2013).
Klann, A. G ., Belanger, A. E ., Abanes-De Mello, A ., Lee, J. Y . & Hatfull, G. F . Characterization of the dnaG locus in Mycobacterium smegmatis reveals linkage of DNA replication and cell division. J. Bacteriol. 180, 65–72 (1998).
Gefter, M. L ., Hirota, Y ., Kornberg, T ., Wechsler, J. A . & Barnoux, C . Analysis of DNA polymerases II and 3 in mutants of Escherichia coli thermosensitive for DNA synthesis. Proc. Natl Acad. Sci. USA 68, 3150–3153 (1971).
van der Ende, A ., Baker, T. A ., Ogawa, T . & Kornberg, A . Initiation of enzymatic replication at the origin of the Escherichia coli chromosome: primase as the sole priming enzyme. Proc. Natl Acad. Sci. USA 82, 3954–3958 (1985).
Karamata, D . & Gross, J. D . Isolation and genetic analysis of temperature-sensitive mutants of B. subtilis defective in DNA synthesis. Molec. Gen. Genet. 108, 277–287 (1970).
Costa, A ., Hood, I. V . & Berger, J. M . Mechanisms for initiating cellular DNA replication. Ann. Rev. Biochem. 82, 25–54 (2013).
Keck, J. L ., Roche, D. D ., Lynch, A. S . & Berger, J. M . Structure of the RNA polymerase domain of E. coli primase. Science 287, 2482–2486 (2000).
Biswas, T ., Resto-Roldan, E ., Sawyer, S. K ., Artsimovitch, I . & Tsodikov, O. V . A novel non-radioactive primase-pyrophosphatase activity assay and its application to the discovery of inhibitors of Mycobacterium tuberculosis primase DnaG. Nucl. Acids Res. 41, e56 (2013).
Biswas, T ., Green, K. D ., Garneau-Tsodikova, S . & Tsodikov, O. V . Discovery of inhibitors of Bacillus anthracis primase DnaG. Biochemistry. 52, 6905–6910 (2013).
Patel, S ., Sprung, A. U ., Keller, B. A ., Heaton, V. J . & Fisher, L. M . Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: implications for the mechanisms of doxorubicin action and cytotoxicity. Mol. Pharmacol. 52, 658–666 (1997).
Ward, D. C ., Reich, E . & Goldberg, I. H . Base specificity in the interaction of polynucleotides with antibiotic drugs. Science 149, 1259–1263 (1965).
Glaser, B. T . et al. A high-throughput fluorescence polarization assay for inhibitors of gyrase B. J. Biomol. Screen 16, 230–238 (2011).
Morlock, G. P ., Metchock, B ., Sikes, D ., Crawford, J. T . & Cooksey, R. C . ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob. Agents. Chemother. 47, 3799–3805 (2003).
Pecere, T . et al. Aloe-emodin is a new type of anticancer agent with selective activity against neuroectodermal tumors. Cancer Res. 60, 2800–2804 (2000).
Floridi, A . et al. Growth inhibition by rhein and lonidamine of human glioma cells in vitro. Anticancer Res. 10, 1633–1636 (1990).
Kuron, A . et al. Evaluation of DNA primase DnaG as a potential target for antibiotics. Antimicrob. Agents Chemother. 58, 1699–1706 (2014).
Smolarz, H. D ., Swatko-Ossor, M ., Ginalska, G . & Medynska, E . Antimycobacterial effect of extract and its components from Rheum rhaponticum. J. AOAC Int. 96, 155–160 (2013).
Etienne, G . et al. The impact of the absence of glycopeptidolipids on the ultrastructure, cell surface and cell wall properties, and phagocytosis of Mycobacterium smegmatis. Microbiology 148 (Pt 10), 3089–3100 (2002).
Piddock, L. J ., Williams, K. J . & Ricci, V . Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis. J. Antimicrob. Chemother. 45, 159–165 (2000).
Stephan, J ., Mailaender, C ., Etienne, G ., Daffe, M . & Niederweis, M . Multidrug resistance of a porin deletion mutant of Mycobacterium smegmatis. Antimicrob. Agents Chemother. 48, 4163–4170 (2004).
Yadav, A ., Bhardwaj, R . & Sharma, R. A . Phytochemical screening and antimicrobial activity of anthraquinones isolated from different parts of Cassia nodosa. Res. J. Med. Plant 7, 150–157 (2013).
Tegos, G ., Stermitz, F. R ., Lomovskaya, O . & Lewis, K . Multidrug pump inhibitors uncover remarkable activity of plant antimicrobials. Antimicrob. Agents Chemother. 46, 3133–3141 (2002).
Duan, F . et al. Haloemodin as novel antibacterial agent inhibiting DNA gyrase and bacterial topoisomerase I. J. Med. Chem. 57, 3707–3714 (2014).
Taylor, J. A ., Mitchenall, L. A ., Rejzek, M ., Field, R. A . & Maxwell, A . Application of a novel microtitre plate-based assay for the discovery of new inhibitors of DNA gyrase and DNA topoisomerase VI. PLoS One 8, e58010 (2013).
Wallace, R. J. Jr. et al. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob. Agents Chemother. 34, 65–70 (1990).
Ruiz-Serrano, M. J . et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob. Agents. Chemother. 44, 2567–2568 (2000).
Mathe, G . et al. Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma. An oncostatic anthracyclin that is rarely cardiotoxic and induces no alopecia. Cancer Chemother. Pharmacol. 1, 259–262 (1978).
Soudy, R ., Chen, C . & Kaur, K . Novel peptide-doxorubucin conjugates for targeting breast cancer cells including the multidrug resistant cells. J. Med. Chem. 56, 7564–7573 (2013).
Grundker, C ., Ernst, J ., Reutter, M. D ., Ghadimi, B. M . & Emons, G . Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers. Oncol. Rep. 26, 629–635 (2011).
Emons, G ., Sindermann, H ., Engel, J ., Schally, A. V . & Grundker, C . Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. Neuroendocrinology 90, 15–18 (2009).
Engel, J. B ., Schally, A. V ., Buchholz, S ., Seitz, S ., Emons, G . & Ortmann, O . Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH). Arch. Gynecol. Obstet. 286, 437–442 (2012).
Sessa, C . et al. Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243). Cancer Chemother. Pharmacol. 44, 403–410 (1999).
Danesi, R . et al. Cardiac toxicity and antitumor activity of 4'-deoxy-4'-iodo-doxorubicinol. Cancer Chemother. Pharmacol. 26, 403–408 (1990).
Yu, S . et al. Synthesis and biological activities of a 3'-azido analogue of doxorubicin against drug-resistant cancer cells. Int. J. Mol. Sci. 13, 3671–3684 (2012).
Acknowledgements
This work was supported by startup funds from the College of Pharmacy at the University of Kentucky (to SG-T and OVT) and by a grant from the Israel Science Foundation (ISF, grant 58/10 to MF). We thank Dr Caixia Hou for helping with purification of Mtb DnaG.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Gajadeera, C., Willby, M., Green, K. et al. Antimycobacterial activity of DNA intercalator inhibitors of Mycobacterium tuberculosis primase DnaG. J Antibiot 68, 153–157 (2015). https://doi.org/10.1038/ja.2014.131
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ja.2014.131
This article is cited by
-
Computational study to select the capable anthracycline derivatives through an overview of drug structure-specificity and cancer cell line-specificity
Chemical Papers (2021)
-
Antimycobacterial activity of an anthracycline produced by an endophyte isolated from Amphipterygium adstringens
Molecular Biology Reports (2018)
-
Inhibition of DNA replication in Staphylococcus aureus by tegaserod
The Journal of Antibiotics (2017)
